Gyre Therapeutics, Inc. (GYRE): Total Assets
$166.13M
As of 2025-12-31
$199.25M
As of 2026-06-30
+25.2%
3-year compound annual growth
+11.9%
5-year compound annual growth
+9.1%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $166.13M | +32.5% | 2026-03-13, Balance as of period end |
| 2024-12-31 | $125.41M | +7.6% | 2026-03-13, Balance as of period end |
| 2023-12-31 | $116.54M | +37.5% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $84.75M | +52.3% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $55.66M | -41.3% | 2023-03-30, Balance as of period end |
| 2020-12-31 | $94.85M | -3.8% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $98.55M | -21.1% | 2021-03-04, Balance as of period end |
| 2018-12-31 | $124.92M | +216.1% | 2020-02-20, Balance as of period end |
| 2017-12-31 | $39.51M | +3.7% | 2019-03-08, Balance as of period end |
| 2016-12-31 | $38.09M | -45.2% | 2018-03-19, Balance as of period end |
| 2015-12-31 | $69.52M | n/m | 2017-03-08, Balance as of period end |
| 2014-12-31 | $2.98M | -98.0% | 2016-03-09, Balance as of period end |
| 2013-12-31 | $145.87M | -23.1% | 2015-03-16, Balance as of period end |
| 2012-12-31 | $189.58M | -26.6% | 2014-03-14, Balance as of period end |
| 2011-12-31 | $258.13M | -1.8% | 2013-03-15, Balance as of period end |
| 2010-12-31 | $262.79M | n/a | 2012-03-06, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $166.13M | +32.5% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $200.46M | -29.8% |
| Xencor Inc (XNCR) | 2025-12-31 | $875.50M | -8.0% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $485.57M | +37.1% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $284.73M | +59.8% |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $346.53M | -25.2% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $239.34M | -5.8% |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $219.47M | -10.2% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $108.42M | -34.1% |
Compare GYRE, URGN, XNCR, TBPH side by side · Screen every company in Pharmaceutical Preparations ↗